Carcinoid Tumor Drug Pipeline Analysis Report 2025
Description
According to the New York State Department of Health, carcinoid tumors are rare. It accounts for 1% of all cancers. The average age of onset for carcinoid tumors is in the early 60s. According to the American Cancer Society, in the United States, approximately 8,000 carcinoid tumors and cancers which start in the gastrointestinal tract are diagnosed each year. The treatment for carcinoid tumor includes surgery, medications, chemotherapy, and targeted drug therapy among others. Several drugs are under clinical trials to evaluate the safety of drugs including immunotherapies. These emerging drugs are expected to slow down the progression of tumor.
Report Coverage
The Carcinoid Tumor Pipeline Insight Report by Expert Market Research gives comprehensive insights into carcinoid tumors clinical trials. It covers various aspects related to the details of each of these drugs under development for carcinoid tumor. The report includes the analysis of over 20+ pipeline drugs and 10+ companies. The carcinoid tumor pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from carcinoid tumor.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing carcinoid tumor pipeline development activities related to carcinoid tumor is covered. Moreover, carcinoid tumor collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Carcinoid Tumor Drug Pipeline Outlook
Carcinoid tumors are slow-growing cancer which can arise in different places throughout the body. Carcinoid tumors are one subset of neuroendocrine tumors that begin usually in the digestive tract or in the lungs. These tumors often don't cause signs and symptoms until reach a later stage. Carcinoid tumors release hormones into the body which cause signs and symptoms including diarrhea or skin flushing. Statistics say that less than 10% of people with carcinoid tumors show symptoms. However, the incidence of symptoms varies based on the location and size of the tumor. Since carcinoid tumors grow slowly, they are not diagnosed usually until age 55-65.
The treatment of carcinoid tumor depends on the size and location of tumor, the types of hormones the tumor secretes, including, medications to control excess hormones, chemotherapy, targeted drug therapy, drugs which deliver radiation directly to the cancer cells, and surgery among others. Medications which are used to control excel hormones are given to slow down tumor growth. Octreotide and lanreotide are administered as injections under the skin. Telotristat is a pill which is used in combination with octreotide or lanreotide sometimes to reduce the symptoms of carcinoid syndrome.
When surgery doesn’t work, chemotherapy is recommended for treating advanced carcinoid tumors. Several studies and research continue to find ways to prevent and manage symptoms of carcinoid tumors. Recent studies have examined the safety of the drug called everolimus against advanced carcinoid tumors. It revealed promising results and proved effective when used to target tumors. This drug was approved by the US FDA in 2016 as a treatment for carcinoid tumors. The changing dynamics are impacting the carcinoid tumor clinical trial landscape significantly.
Carcinoid Tumor – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of carcinoid tumor drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s carcinoid tumor assessment report covers 50+ drug analyses based on drug classes:
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials for carcinoid tumors.
Carcinoid Tumor – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under carcinoid tumor pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. Numerous studies are evaluating the safety of monoclonal antibodies to manage the condition. Monoclonal antibodies such as bevacizumab block tumor growth in several ways as some block tumor cells from growing and spreading while others kill them or carry tumor-killing substances to them. They also stop the growth of cancer by blocking the flow of blood to tumor. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for carcinoid tumor.
Carcinoid Tumor Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR carcinoid tumor report insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in carcinoid tumor clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for carcinoid tumor. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of carcinoid tumor drug candidates.
Drug: 40 mg Paltusotine
The trial is designed to evaluate the safety, and pharmacokinetics (PK) of paltusotine treatment in patients with carcinoid syndrome. The trial is sponsored by Crinetics Pharmaceuticals and is currently under phase II.
Drug: Pasireotide (SOM230)
The objective of the study is to evaluate the SOM230 in patients suffering with metastatic carcinoid tumors. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase II.
Drug: Quarfloxin
Cylene Pharmaceuticals is developing the drug and is currently under phase II. The study is being conducted to evaluate the safety of quarfloxin in patients. The study is evaluating the rate of clinical benefit response to quarfloxin treatment.
Reasons To Buy This Report
The Carcinoid Tumor Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for carcinoid tumor. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into carcinoid tumor collaborations , regulatory environments, and potential growth opportunities within carcinoid tumor pipeline insights.
Key Questions Answered in the Carcinoid Tumor – Pipeline Insight Report
Neuroendocrine Carcinoma Market
Renal Cell Carcinoma Market
Report Coverage
The Carcinoid Tumor Pipeline Insight Report by Expert Market Research gives comprehensive insights into carcinoid tumors clinical trials. It covers various aspects related to the details of each of these drugs under development for carcinoid tumor. The report includes the analysis of over 20+ pipeline drugs and 10+ companies. The carcinoid tumor pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from carcinoid tumor.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing carcinoid tumor pipeline development activities related to carcinoid tumor is covered. Moreover, carcinoid tumor collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Carcinoid Tumor Drug Pipeline Outlook
Carcinoid tumors are slow-growing cancer which can arise in different places throughout the body. Carcinoid tumors are one subset of neuroendocrine tumors that begin usually in the digestive tract or in the lungs. These tumors often don't cause signs and symptoms until reach a later stage. Carcinoid tumors release hormones into the body which cause signs and symptoms including diarrhea or skin flushing. Statistics say that less than 10% of people with carcinoid tumors show symptoms. However, the incidence of symptoms varies based on the location and size of the tumor. Since carcinoid tumors grow slowly, they are not diagnosed usually until age 55-65.
The treatment of carcinoid tumor depends on the size and location of tumor, the types of hormones the tumor secretes, including, medications to control excess hormones, chemotherapy, targeted drug therapy, drugs which deliver radiation directly to the cancer cells, and surgery among others. Medications which are used to control excel hormones are given to slow down tumor growth. Octreotide and lanreotide are administered as injections under the skin. Telotristat is a pill which is used in combination with octreotide or lanreotide sometimes to reduce the symptoms of carcinoid syndrome.
When surgery doesn’t work, chemotherapy is recommended for treating advanced carcinoid tumors. Several studies and research continue to find ways to prevent and manage symptoms of carcinoid tumors. Recent studies have examined the safety of the drug called everolimus against advanced carcinoid tumors. It revealed promising results and proved effective when used to target tumors. This drug was approved by the US FDA in 2016 as a treatment for carcinoid tumors. The changing dynamics are impacting the carcinoid tumor clinical trial landscape significantly.
Carcinoid Tumor – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of carcinoid tumor drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s carcinoid tumor assessment report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Polymer
- Small Molecule
- Gene Therapy
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials for carcinoid tumors.
Carcinoid Tumor – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under carcinoid tumor pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. Numerous studies are evaluating the safety of monoclonal antibodies to manage the condition. Monoclonal antibodies such as bevacizumab block tumor growth in several ways as some block tumor cells from growing and spreading while others kill them or carry tumor-killing substances to them. They also stop the growth of cancer by blocking the flow of blood to tumor. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for carcinoid tumor.
Carcinoid Tumor Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR carcinoid tumor report insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in carcinoid tumor clinical trials:
- Novartis Pharmaceuticals
- CASI Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals Inc.
- Molecular Insight Pharmaceuticals, Inc.
- Neotropix
- Ipsen
- Cylene Pharmaceuticals
- Lexicon Pharmaceuticals
- TerSera Therapeutics LLC
- Endo Pharmaceuticals
- Trio Medicines Ltd.
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for carcinoid tumor. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of carcinoid tumor drug candidates.
Drug: 40 mg Paltusotine
The trial is designed to evaluate the safety, and pharmacokinetics (PK) of paltusotine treatment in patients with carcinoid syndrome. The trial is sponsored by Crinetics Pharmaceuticals and is currently under phase II.
Drug: Pasireotide (SOM230)
The objective of the study is to evaluate the SOM230 in patients suffering with metastatic carcinoid tumors. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase II.
Drug: Quarfloxin
Cylene Pharmaceuticals is developing the drug and is currently under phase II. The study is being conducted to evaluate the safety of quarfloxin in patients. The study is evaluating the rate of clinical benefit response to quarfloxin treatment.
Reasons To Buy This Report
The Carcinoid Tumor Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for carcinoid tumor. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into carcinoid tumor collaborations , regulatory environments, and potential growth opportunities within carcinoid tumor pipeline insights.
Key Questions Answered in the Carcinoid Tumor – Pipeline Insight Report
- What is the current landscape of carcinoid tumor pipeline drugs?
- How many companies are developing carcinoid tumors?
- How many phase III and phase IV drugs are currently present in carcinoid tumor pipeline drugs?
- Which companies/institutions are leading the carcinoid tumor development?
- What is the efficacy and safety profile of carcinoid tumor pipeline drugs?
- What are the opportunities and challenges present in the carcinoid tumor pipeline landscape?
- Which company is conducting major trials for carcinoid tumors?
- What geographies are covered carcinoid tumor for clinical trials?
- What are emerging trends in carcinoid tumor clinical trials?
Neuroendocrine Carcinoma Market
Renal Cell Carcinoma Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Carcinoid Tumor
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Carcinoid Tumor
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Carcinoid Tumor
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Carcinoid Tumor: Epidemiology Snapshot
- 5.1 Carcinoid Tumor Incidence by Key Markets
- 5.2 Carcinoid Tumor – Patients Seeking Treatment in Key Markets
- 6 Carcinoid Tumor: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Carcinoid Tumor: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Carcinoid Tumor, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Carcinoid Tumor Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Carcinoid Tumor Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Lanreotide
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Telotristat etiprate
- 10.2.3 Other Drugs
- 11 Carcinoid Tumor Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Ramucirumab
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Axitinib
- 11.2.3 Other Drugs
- 12 Carcinoid Tumor Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: Pasireotide
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Carcinoid Tumor Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.3 Other Drugs
- 14 Carcinoid Tumor, Key Drug Pipeline Companies
- 14.1 Novartis Pharmaceuticals
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 CASI Pharmaceuticals, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Crinetics Pharmaceuticals Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Molecular Insight Pharmaceuticals, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Neotropix
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Ipsen
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Cylene Pharmaceuticals
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Lexicon Pharmaceuticals
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 TerSera Therapeutics LLC
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Endo Pharmaceuticals
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Trio Medicines Ltd.
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
